Friday, September 24, 2010

Intent to infringe not a requirement for inducing patent infringement

Here's an article by summer student Jamie Goodman on the Bauer v. Easton case and inducing patent infringement in Canada.  The Bauer case is being appealed, and it will be interesting to see what happens.  

 
In Bauer v. Easton,[1] the Federal Court found Easton Sports Canada liable for inducing or procuring the infringement of a patent for a popular Bauer’s skate design.  The judgment explained that to induce infringement an actor must only intend for a third party to follow their influence to achieve a particular end (the infringing act), and that knowledge of the patent’s existence is not a requirement of this tort.  This decision, currently on appeal, has for the first time in Canada provided a firm and definitive statement on the “intent to infringe” requirement for inducing infringement. 

However, because of the Court’s statement that no intent to infringe was required in the “very unique circumstances” of this case (referring to the high degree of control that Easton had exercised over the actions of the third party infringer),[2] the decision, perhaps unintentionally, raises questions about the degree of control that is required to “induce” another, and whether or not this legal standard is consistent with actual expectations held in the business world. 

Background

Direct patent infringement may be characterized as a strict liability tort, as liability can be attached to an infringing party even if it never had any intention of violating the rights of a valid patent holder, or any knowledge that the patent it was violating existed.  On the other hand, the law pertaining to inducing (or procuring) patent infringement – whereby one party influences another party to directly infringe a patent, often present in outsourcing arrangements among manufacturers - has not been so clear cut.

There are three basic requirements for inducing infringement in Canadian law: (1) there must be an infringing act committed by the direct infringer; (2) this infringing act must have been influenced by the alleged inducer (akin to a “but for” analysis), and; (3) the influence must have been knowingly exercised and intended by the inducer.[3] 

A source of uncertainty in law, both in Canada and abroad, has arisen from the third requirement, for it has raised questions as to the level of knowledge and intent that is needed to attach liability to an allegedly inducing party.  For example, does an alleged inducer need to have knowledge of the patent at issue, such that the inducer specifically intended for the influenced party to infringe that patent?  Or, is the simple intention that the inducer’s directions be followed enough to attach liability?  Or, might the answer fall somewhere in between, such as liability for wilful blindness towards existing patents?

In Bauer v. Easton, Justice Gauthier reiterated the principle that the tort of inducing infringement is to be treated the same as direct infringement, thereby clarifying that an alleged inducer need not be aware of the patent at issue in order to be found liable for influencing its infringement. 

Unfortunately, in answering this question, the Federal Court managed to raise a different question, one that could become a source of contention in future patent infringement cases.  To what extent does the level of control that an alleged inducer exhibits over the direct infringer affect the intent threshold required for liability?  Furthermore, would it be fair for courts to attach liability to a business if it had almost no control over the third party’s actions (and thereby also had no foreseeability of any potential patent infringement)?

Bauer v. Easton

In this case, Easton Sports Canada Inc. was found to have infringed a patent belonging to Bauer Hockey Corp. (the patent described Bauer’s popular “Vapor 8” ice skate model).  Based on the facts of the case, Justice Gauthier was able to easily determine that Easton was responsible for inducing a third party into directly infringing Bauer’s patent. 

The Easton skates were outsourced for manufacture to a third party company known as Rock Forest Inc.  While Rock Forest employees did assist with some minor aspects of the skates’ composition (such as development of the footwear pattern), it was clear on the evidence that Easton had significant control over the entire manufacturing process.  Not only did Easton employees fully conceive of the design and conception of the skates (presumably without the aid of Bauer’s patent), but Easton went as far as to station one of their employees at the Rock Forest premises to directly oversee production of the skates. 

As a result of this overt relationship of principal-to-agent influence and control, the Federal Court was given a solid opportunity to shed light on the law of inducing infringement in Canada. 

Inducement to Act Must Be Intentional, Resulting Infringement Need Not Be

Despite arguments that were put forth by Easton, Justice Gauthier was adamant in proclaiming that “there is no case law stating clearly that one could not infringe by inducement or procurement unless it knew of the patent.”[4]

To be held liable, the alleged inducer must only intend for the actions of the direct infringer (the third party manufacturer) to be completed in accordance with whatever directions were given by the inducer.  Whether the inducing party intended for infringement of a patent to occur is completely irrelevant to the analysis. 
           
The Court explained that to hold otherwise would “create an unwarranted and unjustifiable distinction” between companies who manufacture their own products and companies who instead choose to outsource their production by giving specific instructions.[5] If there were to be a higher threshold for intent, any third party who had been contracted to simply follow instructions could unfairly be held as the only party responsible for any resulting patent infringement (as the inducing party could deliberately avoid, or deny, having any knowledge of the interfering patents).  The lower threshold of intent in Bauer v. Easton therefore avoids situations where a mastermind can escape punishment while their servant is found guilty.[6] 

In the U.S., courts have been split on what level of intent should be required for inducing infringement, known there as “active inducement.”  In one case, it was actually conceded that this area of the law is plagued with a “lack of clarity.”[7]  Competing American precedents have held that (similar to Canadian law) there is no “intent to infringe” requirement,[8] while others have held entirely the opposite.[9]  As recently as February of 2010, the U.S. Federal Circuit has endorsed the position that active inducement may be found at least where the inducer has shown “deliberate indifference” to a patent.[10] 

The Legal Model is Misaligned with the Practical Reality

The Supreme Court of Canada has already declared that patent infringement is a “statutory tort,”[11] and the principle that inducing infringement is akin to direct patent infringement has been present in Canadian law for a long time.[12]  Bauer v. Easton affirmed this, stating that “inducing or procuring another to make or construct a patented invention is not a tort distinct from that of infringement.”[13]  This entails that the low threshold for intent should be applied evenly in any case involving patent infringement, regardless of the reasonable expectations or business arrangements among the parties involved. 

Nonetheless, the Federal Court’s acknowledgment of this overlap of torts - when read in conjunction with the facts of the case - may muddy the waters in a new vein.  “Here, through [an Easton employee’s] involvement … Easton was actually participating in the making of the skates that are now found to infringe.”[14]  The Court’s judgment was straightforward precisely because Easton exercised such unequivocal control over the actual infringer of the patent; the characterization of Easton’s liability as “inducement” is, in this case, interchangeable with a characterization of “directly infringing.”
 
Whether or not a party needs knowledge of a patent (or intent to infringe) in order to be liable for inducing infringement has often been a source of confusion in Canada.  As such, the relationship between the law on this matter and the expectations of real actors in the business world is uncertain.  By all means, where the inducing infringer exercises tremendous control over the actor who actually infringed, it is justifiable to overlook intent, because that inducer may just as well be liable for direct infringement. 
           
Yet, what if, instead, Easton had actually only exercised minimal control over its third party manufacturer (such that Easton did not even play a role in the design of the infringing skate)?  Yes, this might still qualify as inducing infringement according to the law (since the law on its face only requires minimal influence to be exercised by the inducer); but, in this hypothetical, it would be highly unlikely that Easton could have reasonably expected to be implicated in the unforeseen infringement caused by a third party.  Is it not problematic that the notion of “reasonable expectations” - a focal point of tort law - is given no weight when assessing the statutory tort of inducing patent infringement? 

Drifting Towards Common Design?

By essentially lumping the tort of inducing infringement together with direct infringement, Bauer v. Easton appears to be steering Canadian law in the direction followed by English Courts via the doctrine of infringement by common design (also known as “joint infringement”), which holds both the inducer and the direct infringer equally liable for patent infringement.  The standard for this type of liability also neglects knowledge of the infringed patent and limits the intent threshold to infringe, not unlike Canadian law.  More notably, infringement by common design barely contemplates issues of influence or control (which are pivotal to a finding of induced infringement in Canada).  In a leading British case that was cited by Justice Gauthier in Bauer v. Easton, it was stated of infringement by common design that: “This idea does not…call for any finding that the secondary party has explicitly mapped out a plan with the primary offender.  Their tacit agreement will be sufficient.”[15] 

Thus, where there is an agreement in place between two parties to work together under some type of business/manufacturing arrangement, any patent infringement by either party, regardless of the involvement of the other, could render both parties liable as joint infringers.  This is not yet an accepted position in Canadian law, and infringement by common design could greatly expand the risks involved in any joint business venture in an industry where patents are abundant. 
           
In the U.S., meanwhile, “joint infringement” (or, “indirect infringement”) might impose a higher burden on plaintiffs seeking to enforce liability on multiple parties who have together carried out all of the claims of a patent.  This area of somewhat unsettled law lacks a bright-line test, but does put tremendous emphasis on a factual assessment of the amount of direction and control present in each case.[16]  Ideally, significant evidence must be put forth by the plaintiff indicating contractual agreements between the direct infringer and the controlling party; anything less, and the plaintiff’s action may be subject to dismissal or summary judgment.

Stick to the Facts

The U.S. doctrine of “joint infringement” aligns more closely with the facts of Bauer v. Easton than the alternative U.S. approach of active inducement (which requires a specific intent to infringe).  Canadian law, however, does not distinguish between active inducement and joint infringement; instead, each case will be assessed by the same standards of “inducing infringement.”  As a result, the lines for when multiple parties can be held mutually accountable for the infringement of a Canadian patent remain unclear.
           
Eventually, a situation that falls hazily between the second and third prongs of Canada’s three part test for inducing infringement (the direct infringement must have been influenced by another party, and that party’s influence must have been intentional) is likely to arise; in this situation, there would be a limited relationship between the parties and a minimal degree of control exercised from one over the other.  In such a case - whereby the opportunity would arise for the influencing party to claim ignorance as a potential defense - perhaps Canadian Courts could best decide on infringement liability by avoiding any bright-line test altogether, and instead focus more closely on the factual circumstances at hand.  To do otherwise (i.e. by attempting to decide the case using existing legal boundaries on inducing infringement) might conflate inducement and joint infringement principles even further, adding more confusion to this area of the law and more uncertainty for the patent holders and third parties involved.

Conclusion

Pending the appeal of Bauer v. Easton, the law in Canada is settled on the premise that inducing patent infringement does not require knowledge of the patent’s existence.  Still, the chances that a business will be surprised to find itself responsible for patent infringement – even though that business may have only played a very limited, and unintentional, role in having influenced the resulting infringement caused by a third party – seems possible.  When the Federal Court is inevitably faced with a patent infringement action whereby the inducing infringer exercised substantially less control and influence than Easton has done, issuing a judgment of liability via our existing guidelines for “inducing infringement” may prove to be much more contentious and controversial than it was in the battle over the Vapor 8 ice skate design. 


[1] Bauer Hockey Corp. and Nike International Limited v. Eason Sports Canada Inc., 2010 FC 361 [Bauer v. Easton].
[2] Bauer v. Easton, at para 209.
[3] Dableh v. Ontario Hydro, [1996] 3 F.C. 751 (Fed C.A.); leave to appeal refused (1997), 1997 CarswellNat 3240 (S.C.C.).
[4] Bauer v. Easton, at para 197.
[5] Ibid, at para 203.
[6] Lemley, Mark A., Inducing Patent Infringement. UC Davis Law Review, Vol. 39, p. 225, 2005; Stanford Law School, Public Law Working Paper No. 110. Available at SSRN: http://ssrn.com/abstract=772264, at 21.
[7] Insituform Techs. V. CAT Contracting, 385 F. 3d 1360 (Fed. Cir. 2004).
[8] Hewlett-Packard v. Bausch & Lomb, 909 F. 2d 1464 (Court of Appeal, Fed. Cir. 1990).
[9] Manville Sales v. Paramount Sys., 917 F. 2d 544 (Fed. Cir. 1990).
[10] SEB S.A. v. Montgomery Ward & Co., Inc., 594 F.3d 1360 (Fed. Cir. 2010).
[11] Bristol-Myers Squibb Co. v. Canada (Attorney General), 2005 SCC 26, 39 C.P.R. (4th) 449, at para 134.
[12] Hatton v. Copeland-Chatterson Co., 10 Ex. C.R. 224, 1906 CarswellNat 10, at para 16.
[13] Bauer v. Easton, at para 199.
[14] Ibid., at para 205.
[15] Bauer v. Easton, at para 206, citing Unilever plc v. Gillette (UK) Limited, [1989] R.P.C. 583 (U.K.C.A.) at p. 609.
[16] Eckstein, Maya M. and Spalding, Shelley L., “What Remains of Joint Patent Infringement?” IP Litigator, September/October 2009.

Friday, September 10, 2010

USPTO Data: CIPO?

Those of you who know me well know that in the past I have harped on patent office statistics like pendency and backlogs.  I think they are important - central, critical even - to understanding how patent law functions in a country. 

Well, the USPTO has certainly taken the idea of transparency in such matters to heart.  Check THIS out.

So, CIPO...  when can we expect a similar level of disclosure?  ;) 


(adding a comparison of CIPO stats to USPTO stats for corresponding applications would be nice too...)

Thursday, September 9, 2010

Interesting Article on "Tax Accountant Priviilege?"

An interesting article "Tax Accountant Privilege" in this week's Lawyer's Weekly.   The lead:

"Should privilege extend to communications between tax accountants and their clients? As there is “no tax without law,” advising on the law is what tax accountants do. The English Court of Appeal is now examining whether privilege should be based on the nature of the advice or the qualifications of the person providing it." 

With all due respect to the tax profession, this is interesting mainly because of the similarities to the issue of privilege for communications between patent agents and their clients.  ;)  To paraphrase, as there is "no patents without law", advising on the law is what patent agents do. 

One of the arguments raised against privilege for communications between clients and patent agents is that it would open the floodgates to let communications between clients and the great unwashed (i.e. tax accountants) also attract privilege.  I don't know how credible that actually is (what do you need to do to become a tax accountant anyway?).    

I have an article coming out in Managing Intellectual Property in October on privilege for communications with foreign lawyers and patent agents in Canada, for those who are interested.  

Thursday, September 2, 2010

Generic Drug Supply Problems

The National Post has an article on shortages in the supply of about 10-15 generic drugs.

The generic drug companies point to manufacturing and supply problems - and remember that this is a global industry, so we're often talking about off-shore supply problems - but the journalists can't help wondering if this reflects the recent changes in generic drug pricing regimes.

Wednesday, September 1, 2010

Incidentally...

If you think that Investor/State disputes are only won by the investors, the Canadian government won a claim last week against Chemtura, a US company that sought $78 million (US) in compensation for banning the use of lindane, which is a fungicide. 

I have no idea about the details of this case, so this may have be a complete change of topic ;)

but in general, critics of investor/state dispute provisions often talk as if these provisions prohibit governments from taking action.  But often the only restraint on the government is procedural - i.e. you have to pass/make the regulation in fair manner.  But governments can actually pass and implement legislation/regulation, and often the procedural or fairness hurdles are hardly high.

Not to say that there aren't significant and real concerns about investor/state provisions in trade deals.   Here's a "Public Statement on the International Investment Regime", posted yesterday on the OHLS website, which appears to be led by Professors Gus van Harten of Osgoode Hall and David Schneiderman of the University of Toronto. 

 

Wednesday, August 25, 2010

AbitibiBowater gets $130 Million fof NAFTA claim

Remember the fuss back when Newfoundland  took away water and timber rights and expropriated hydroelectric assets from AbitibiBowater?  Newfoundland said that under the terms of the 1905 lease, these rights were all contingent on Abitibi operating a mill in the province.  Since Abitibi closed the mill (itself a long drawn out affair), all of these assets reverted to the provincial government.

Abitibi, which is a Delaware company, threatened to launch an investor-state complaint under Chapter 11 of NAFTA.

Today, the Canadian federal government settled with Abitibi for $130 million - which must be one of the largest, if not the largest, NAFTA Chapter 11 payouts.

http://www.theglobeandmail.com/report-on-business/ottawa-pays-abitibibowater-130-million-for-expropriation/article1683906/

Note that since this is a NAFTA issue, its the Federal government that is settling the matter, not NL.

   

Thursday, August 19, 2010

Swiss Claims in Canada

Here's an article by summer student Shaughnessy Hawkins, on Swiss claims, which she published recently on lexology

Swiss Claims in Canada


Swiss claims arose to circumvent restrictions on the patentability of a medicinal use of an already-patented compound.  Canadian courts are faced with the difficulty of determining how to interpret such claims, particularly in light of their inherent discrepancy between form and substance. Both European and Canadian courts have recently considered such claims and their legal grounding.  A review of these decisions reveals strategic implications for parties considering Swiss claims in the Canadian context, and raises questions about the future treatment of Swiss claims under Canadian law.

Overview of Swiss Claims

Swiss claims are claims of the form “the use of [compound X] in the manufacture of a medicament for the treatment of [disorder Y]” where compound X is previously known. They are therefore (when construed literally) aimed at the manufacture of the substance, rather than the use, thus circumventing any restrictions against patenting a subsequent use.

Swiss claims highlight an ongoing struggle faced by the courts: whether the language of the claims or the substance of the invention should guide the process of construing the claims. By giving weight to the substance of the invention, the court protects the patentee and her idea. By giving weight to the language of the claims, the court protects the public by providing clear notice as to the scope and contents of the patentee’s monopoly. Particularly in the case of subsequent patents involving the same compounds, courts are attuned to the risk of evergreening by a patentee to protect its monopoly.

Canadian Law

What was once a blanket prohibition in Canada against patents for medical uses has softened into a prohibition against patenting methods of medical treatment. The result of such a shift has been that in recent years, use claims have generally been accepted by Canadian courts, provided they do not amount to methods of medical treatment. Hence there is no particular need to use a Swiss claims structure in Canada.  Still, such claims exist in many Canadian patents, reflecting international claiming practices.

However, there is more at stake in the Canadian context than mere patentability. Canada has a regime for generic manufacturers seeking entry into the market called the Patented Medicine (Notice of Compliance) or PM(NOC) Regulations, similar to the Hatch-Waxman Act in the United States.  Under the PM(NOC) Regulations, a patent containing a claim to the use of a medicinal ingredient is considered eligible for listing under the patent registry, similar to the Orange Book in the US, and the generic company must address the claim prior to gaining entry into the market.  In contrast, methods of manufacturing are not eligible for listing and do not need to be addressed. In light of these regulations, what weight should Canadian courts give to the inclusion of the terms “for the manufacture of a medicament useful for…”?

As a general matter, courts have placed increasing emphasis on the specific language used in a patent claim in the past decade. However, interpreting so-called Swiss claims literally would require judges to deliver a potentially hefty blow to patentees, who might then be forced to restructure their claims solely to adapt to Canadian policies. Courts therefore give careful consideration to the issue of dealing with Swiss claims.

Justice Hughes of the Federal Court of Canada recently considered the development of law dealing with Swiss Claims both in Canada and abroad in Merck Co. v. Pharmascience, 2010 FC 510. In this case, he suggested that the treatment of Swiss claims by Canadian courts has been somewhat inconsistent,[1] and pointed to two such cases in support of this fact. However, I would argue that these cases, as well as Justice Hughes’ own decision, are relatively consistent in their approach. When faced with Swiss claims, the courts seem to give greater weight to the substance of the invention, or what is truly being claimed, as opposed to the language of the claim. While the substance of the invention may have been different in each case, leading to different outcomes, the actual approach taken by the judges seems consistent.

For example, in Abbott Laboratories v. Canada (Minister of Health)[2], the Federal Court of Appeal upheld the trial judge’s finding that a claim for “the use of [clarithromycin] Form 0-ethanolate in the preparation of [clarithromycin] Form II for use as an antibiotic” was not a claim for the use of a medicine eligible for listing under the PM(NOC) regulations because the words “for use as an antibiotic” added nothing to the construction. It was well-established that clarithromycin’s only use was as an antibiotic. Hence what constituted the actual invention, or the substance thereof, was the method of preparation of Form II, and this is what guided the court’s interpretation of the claims in this context.

Similarly, in Pfizer Canada Inc. v. Apotex Inc.,[3] Mosley J. found that a claim of the form “the use of a compound of formula (I) […] for the manufacture of a medicament for the curative or prophylactic treatment of an erectile dysfunction in man”, coupled with other claims to various forms of sildenafil in the treatment of erectile dysfunction in man, was directed to the use of the medicine, the manufacture being secondary. This was influenced by the fact that all of the claims described the use of the medicine, while only some referenced the manufacture, leading the judge to read in that the use was the key element of the invention.

In the recent Merck decision, Justice Hughes held that a claim of the form “the use of finasteride for the preparation of a medicament adapted for oral administration useful for the treatment of male pattern baldness in a person and wherein the dosage amount is about 1 mg” was directed to the use of a medicament for treatment of a human condition at a particular fixed dosage, given that the manufacture of the medicament and its use in the treatment of male pattern baldness generally was already well-known. Once again, the judge considered what the inventive concept, or substance of the invention was, and construed the claim in that light.

The Canadian jurisprudence suggests that courts have not considered the Swiss-style structure of a claim to be determinative in the analysis, regardless of the context. Rather, courts have instead considered what has in fact been allegedly invented.

Swiss Claims under European Law

Both the UK Court of Appeal and the Enlarged Board of Appeal of the European Patent Office (the “EBA”) have recently considered the status of Swiss claims under European law. In Britain, the Court of Appeal considered the issue in Actavis UK Ltd. V. Merck  Co. Inc.[4] The decision held that Swiss claims are acceptable claims for both new uses as well as new dosage forms of an old compound. The court pointed out that the patent generally does not really teach the manufacture, and may in fact teach how to actually treat a patient. In line with previous jurisprudence on the subject, they held that while a Swiss claim is necessary for the purpose of avoiding the prohibition on claims to the use of medicines, the structure will be ignored when considering issues such as novelty.

Shortly after Actavis was decided, the EBA considered the same issue in Kos Life Sciences.[5] In Kos, the EBA altered their longstanding approach to Swiss claims. Previously, the construction of Swiss claims was considered a necessary and acceptable mechanism to circumvent the prohibition on claims to the use of medicines, though their structure was ignored when considering issues such as novelty. However, the prohibition that gave rise to a need for Swiss claims had since been removed.[6] Given that Swiss claims also lack a connection between what is being claimed and what is in fact novel, the EBA held that, prospectively, such claims will not be read in, i.e., will be construed literally.

Strategic Considerations for Patentees

Canada’s most recent decision on Swiss claims, Merck, considered developments in European patent law, yet gave no suggestion that Canadian law would or should move in a similar direction. However, it may be the case that as Swiss claims come before courts in both Europe and Canada, the Canadian approach may also shift away from reading in the substance of the invention to create more cohesive and predictable treatment internationally. Canadian courts and the Canadian Intellectual Property Office often draw from international treatment of claims in issue.  Such a move would also increase predictability in the interpretation of claims in the Canadian courts.  Ultimately, it may be the case that as a result of the Kos decision, fewer Swiss claims will be filed abroad, and subsequently in Canada.

          Parties filing (or responding to) a Notice of Allegation against a patent containing a Swiss claim should also be attuned to the various characterizations that are possible of such claims and may want to consider addressing multiple such characterizations in the alternative. In Merck, for example, Justice Hughes dismissed Pharmascience’s arguments that the claim was for the manufacture, because the Notice of Allegation had characterized the claims as being for the dosage.

Conclusion

          Swiss claims are difficult to construe because their structure often does not reflect the underlying substance of the invention.  Canadian courts have tended to emphasize the inventive concept rather than the language of the claim; however, European courts have recently shifted towards a literal interpretation. This may eventually result in Canadian practice conforming with the new European approach.  In the meantime, parties considering Swiss claims should bear in mind the possibilities for alternative interpretations under Canadian law.


Shaughnessy Hawkins
Summer Student
Gilbert’s LLP




[1] Merck Co. v. Pharmascience Inc., 2010 FC 510.
[2] (2007), 59 C.P.R. (4th) 1 (F.C.A.).
[3] (2007), 61 C.P.R.(4th) 305 (F.C.).
[4] [2008] EWCA Civ 444, [2009] 1 All E.R. 196 (21st May 2008) [Actavis].
[5] Case No. G 0002/08, 19 February 2010
[6] Article 54(5) of the European Patent Convention now permits purpose-related protection for any further specific use of a known medicament in a method of therapy.